128 related articles for article (PubMed ID: 28622584)
1. STMN1 as a candidate gene associated with atypical meningioma progression.
Liu H; Li Y; Li Y; Zhou L; Bie L
Clin Neurol Neurosurg; 2017 Aug; 159():107-110. PubMed ID: 28622584
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of STMN1 is associated with the prognosis of meningioma patients.
Wang H; Li W; Wang G; Zhang S; Bie L
Neurosci Lett; 2017 Jul; 654():1-5. PubMed ID: 28625575
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
4. A microRNA expression signature predicts meningioma recurrence.
Zhi F; Zhou G; Wang S; Shi Y; Peng Y; Shao N; Guan W; Qu H; Zhang Y; Wang Q; Yang C; Wang R; Wu S; Xia X; Yang Y
Int J Cancer; 2013 Jan; 132(1):128-36. PubMed ID: 22674195
[TBL] [Abstract][Full Text] [Related]
5. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
6. The correlation of clinical and chromosomal alterations of benign meningiomas and their recurrences.
Och W; Szmuda T; Kulbacki K; Witek K; Sikorska B; Zakrzewska M; Springer J; Reszeć J; Parda A; Liberski PP
Neurol Neurochir Pol; 2016; 50(6):395-402. PubMed ID: 27480481
[TBL] [Abstract][Full Text] [Related]
7. Benign versus atypical meningiomas: risk factors predicting recurrence.
Nowak A; Dziedzic T; Krych P; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(1):1-10. PubMed ID: 25666766
[TBL] [Abstract][Full Text] [Related]
8. Whole Exome Sequencing of Multiple Atypical Meningiomas in a Patient without History of Neurofibromatosis Type II: A Case Report.
Lyu J; Quan Y; Wang JB; Gong SP
Am J Case Rep; 2020 May; 21():e923928. PubMed ID: 32461543
[TBL] [Abstract][Full Text] [Related]
9. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
10. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
[TBL] [Abstract][Full Text] [Related]
11. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
12. Intracranial angiomatous meningiomas: A 15-year, multicenter study.
Ben Nsir A; Chabaane M; Krifa H; Jeme H; Hattab N
Clin Neurol Neurosurg; 2016 Oct; 149():111-7. PubMed ID: 27513979
[TBL] [Abstract][Full Text] [Related]
13. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
14. Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence.
Urbschat S; Rahnenführer J; Henn W; Feiden W; Wemmert S; Linsler S; Zang KD; Oertel J; Ketter R
Int J Oncol; 2011 Dec; 39(6):1601-8. PubMed ID: 21922133
[TBL] [Abstract][Full Text] [Related]
15. A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.
Chen WC; Vasudevan HN; Choudhury A; Pekmezci M; Lucas CG; Phillips J; Magill ST; Susko MS; Braunstein SE; Oberheim Bush NA; Boreta L; Nakamura JL; Villanueva-Meyer JE; Sneed PK; Perry A; McDermott MW; Solomon DA; Theodosopoulos PV; Raleigh DR
Neurosurgery; 2020 Dec; 88(1):202-210. PubMed ID: 32860417
[TBL] [Abstract][Full Text] [Related]
16. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
18. Progression-Free Survival and Factors Associated with Postoperative Recurrence in 126 Patients with Atypical Intracranial Meningioma.
Phonwijit L; Khawprapa C; Sitthinamsuwan B
World Neurosurg; 2017 Nov; 107():698-705. PubMed ID: 28838877
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Role of Histone 3 Lysine Methyltransferase and Demethylase in Regulating Apoptosis Predicting the Recurrence of Atypical Meningioma.
Lee SH; Lee EH; Lee SH; Lee YM; Kim HD; Kim YZ
J Korean Med Sci; 2015 Aug; 30(8):1157-66. PubMed ID: 26240495
[TBL] [Abstract][Full Text] [Related]
20. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
